Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 5
2022 4
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Targeting SHP2 Signaling in Lung Cancer.
Imbody D, Arce K, Solanki HS, Haura EB, Pellini B. Imbody D, et al. Among authors: pellini b. J Thorac Oncol. 2024 Jan;19(1):18-24. doi: 10.1016/j.jtho.2023.08.009. Epub 2023 Aug 11. J Thorac Oncol. 2024. PMID: 37574134 Review. No abstract available.
Overcoming KRAS-Mutant Lung Cancer.
Luo J, Ostrem J, Pellini B, Imbody D, Stern Y, Solanki HS, Haura EB, Villaruz LC. Luo J, et al. Among authors: pellini b. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-11. doi: 10.1200/EDBK_360354. Am Soc Clin Oncol Educ Book. 2022. PMID: 35412860 Free article.
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Pellini B, Madison RW, Childress MA, Miller ST, Gjoerup O, Cheng J, Huang RSP, Krainock M, Gupta P, Zou W, Shames DS, Moshkevich S, Ballinger M, Liu MC, Young A, Srivastava MK, Oxnard GR, Socinski MA. Pellini B, et al. Clin Cancer Res. 2023 Nov 14;29(22):4596-4605. doi: 10.1158/1078-0432.CCR-23-1578. Clin Cancer Res. 2023. PMID: 37702716 Free PMC article.
Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.
Chen K, Shields MD, Chauhan PS, Ramirez RJ, Harris PK, Reimers MA, Zevallos JP, Davis AA, Pellini B, Chaudhuri AA. Chen K, et al. Among authors: pellini b. Mol Diagn Ther. 2021 Nov;25(6):757-774. doi: 10.1007/s40291-021-00559-x. Epub 2021 Nov 1. Mol Diagn Ther. 2021. PMID: 34725800 Free PMC article. Review.
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
Bodor JN, Patel JD, Wakelee HA, Levy BP, Borghaei H, Pellini B, Costello MR, Dowell JE, Finley G, Huang CH, Neal JW, Nieva JJ, Puri S, Socinski MA, Thomas C, Ross EA, Litwin S, Clapper ML, Treat J. Bodor JN, et al. Among authors: pellini b. Clin Lung Cancer. 2023 Nov;24(7):e242-e246. doi: 10.1016/j.cllc.2023.05.003. Epub 2023 May 11. Clin Lung Cancer. 2023. PMID: 37451930 Clinical Trial.
23 results